Invention Grant
US07662825B2 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
失效
N-吡嗪基 - 苯基磺酰胺及其在治疗趋化因子介导的疾病中的应用
- Patent Title: N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases
- Patent Title (中): N-吡嗪基 - 苯基磺酰胺及其在治疗趋化因子介导的疾病中的应用
-
Application No.: US10501510Application Date: 2003-01-14
-
Publication No.: US07662825B2Publication Date: 2010-02-16
- Inventor: Andrew Baxter , Timothy Johnson , Nicholas Kindon , Bryan Roberts , Michael Stocks
- Applicant: Andrew Baxter , Timothy Johnson , Nicholas Kindon , Bryan Roberts , Michael Stocks
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: Morgan Lewis & Bockius LLP
- Priority: SE0200119 20020116; SE0201857 20020617
- International Application: PCT/SE03/00041 WO 20030114
- International Announcement: WO03/059893 WO 20030724
- Main IPC: A61K31/4965
- IPC: A61K31/4965 ; C07D241/02
Abstract:
The invention provides N-pyrazinyl-phenyl-sulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.
Public/Granted literature
- US20060025423A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases Public/Granted day:2006-02-02
Information query
